Related Experiment Video

Updated: Feb 2, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

413

Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for

Shinji Kohsaka1, Mark Petronczki2, Flavio Solca2

  • 1Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.

Future Oncology (London, England)
|November 9, 2018
PubMed

Insights

Acquired resistance to epidermal growth factor receptor (EGFR) targeted tyrosine kinase inhibitors (TKIs) is inevitable in non-small-cell lung cancer. Understanding resistance mechanisms may allow for optimal sequential TKI use, improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Epidermal growth factor receptor (EGFR) targeted tyrosine kinase inhibitors (TKIs) have transformed non-small-cell lung cancer (NSCLC) treatment.
  • Acquired resistance to EGFR TKIs is a significant clinical challenge, driven by tumor evolution and heterogeneity.
  • Multiple molecular mechanisms underlie acquired resistance to EGFR-targeted therapies.

Purpose of the Study:

  • To review mechanistic differences between first-, second-, and third-generation EGFR TKIs.
  • To explore how these mechanistic differences relate to clinical activity from a clonal evolution perspective.
  • To hypothesize on the optimal sequential use of EGFR TKIs based on resistance mechanisms.

Main Methods:

  • Review of existing literature on EGFR TKI mechanisms of action.
  • Analysis of tumor resistance mechanisms in EGFR mutation-positive NSCLC.
  • Speculative analysis based on clonal evolution principles.

Main Results:

  • First-, second-, and third-generation EGFR TKIs exhibit distinct mechanistic profiles.
  • Tumor heterogeneity and clonal evolution contribute to the development of resistance.
  • Differences in TKI generation may influence clinical efficacy and resistance patterns.

Conclusions:

  • Understanding the molecular basis of resistance is crucial for effective cancer treatment.
  • Optimal sequential administration of EGFR TKIs may overcome or delay acquired resistance.
  • Personalized treatment strategies based on resistance mechanisms can prolong chemotherapy-free survival and benefit patients.
Keywords:
EGFRNSCLCacquired resistanceafatinibclonal evolutionerlotinibgefitinibosimertinib

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.1K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.6K

Related Concept Videos

Mutations01:39

Mutations

Overview
94.5K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.0K